Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Published:2010-06 Issue:9733 Volume:375 Page:2223-2233
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Bailey Clifford J,Gross Jorge L,Pieters Anne,Bastien Arnaud,List James F

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Metabolic syndrome pandemic;Grundy;Arterioscler Thromb Vasc Biol,2008

2. Evaluation of risk factors for development of complications in type II diabetes in Europe;Liebl;Diabetologia,2002

3. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004;Dodd;Curr Med Res Opin,2009

4. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study);Harris;Diabetes Res Clin Pract,2005

5. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America;Stewart;Rev Panam Salud Publica,2007

Cited by 721 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative risk of infection of medications used for type 2 diabetes;Expert Opinion on Drug Safety;2024-09-11

2. Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study;Diabetes, Obesity and Metabolism;2024-09-02

3. Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure;Journal of Cardiac Failure;2024-08

4. Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis;The Journal of Clinical Pharmacology;2024-08

5. SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis;Biomedicine & Pharmacotherapy;2024-08